BACKGROUND: Graft arteriosclerosis (GA) is an important factor limiting long-term outcomes after organ transplantation. We have used a chimeric humanized mouse system to model this arteriopathy in human vessels, and found that the morphologic and functional changes of experimental GA are interferon (IFN)-gamma dependent. This study evaluated whether 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, described as inhibitors of IFN-gamma production, affect GA in our model. METHODS: C.B.-17 severe combined immunodeficiency-beige mice were transplanted with human artery segments as aortic interposition grafts and inoculated with allogeneic human peripheral blood mononuclear cells (PBMCs) or replication-deficient adenovirus encoding human IFN-gamma. Transplant arteries were analyzed from recipients treated with vehicle vs. atorvastatin or simvastatin at different doses. The effects of statins on T-cell alloresponses to vascular endothelial cells were also investigated in vitro. RESULTS: Graft arteriosclerosis-like arteriopathy induced by PBMCs was reduced by atorvastatin at 30 mg/kg/day or simvastatin at 100 mg/kg/day that correlated with decreased graft-infiltrating CD3+ T cells. Circulating IFN-gamma was also reduced, as were graft IFN-gamma and IFN-gamma-inducible chemokine transcripts and graft human leukocyte antigen-DR expression. Graft arteriosclerosis directly induced by human IFN-gamma in the absence of human PBMCs was also reduced by atorvastatin, but only at the highest dose of 100 mg/kg/day. Finally, atorvastatin decreased the clonal expansion and production of interleukin-2, but not IFN-gamma, by human CD4+ T cells in response to allogeneic endothelial cells in coculture. CONCLUSIONS: Our results suggest that a benefit of statin administration in transplantation may include amelioration of GA primarily by inhibiting alloreactive T-cell accumulation and consequent IFN-gamma production and secondarily through suppression of the arterial response to IFN-gamma.
BACKGROUND:Graft arteriosclerosis (GA) is an important factor limiting long-term outcomes after organ transplantation. We have used a chimeric humanized mouse system to model this arteriopathy in human vessels, and found that the morphologic and functional changes of experimental GA are interferon (IFN)-gamma dependent. This study evaluated whether 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, described as inhibitors of IFN-gamma production, affect GA in our model. METHODS: C.B.-17 severe combined immunodeficiency-beige mice were transplanted with human artery segments as aortic interposition grafts and inoculated with allogeneic human peripheral blood mononuclear cells (PBMCs) or replication-deficient adenovirus encoding humanIFN-gamma. Transplant arteries were analyzed from recipients treated with vehicle vs. atorvastatin or simvastatin at different doses. The effects of statins on T-cell alloresponses to vascular endothelial cells were also investigated in vitro. RESULTS: Graft arteriosclerosis-like arteriopathy induced by PBMCs was reduced by atorvastatin at 30 mg/kg/day or simvastatin at 100 mg/kg/day that correlated with decreased graft-infiltrating CD3+ T cells. Circulating IFN-gamma was also reduced, as were graft IFN-gamma and IFN-gamma-inducible chemokine transcripts and graft human leukocyte antigen-DR expression. Graft arteriosclerosis directly induced by humanIFN-gamma in the absence of human PBMCs was also reduced by atorvastatin, but only at the highest dose of 100 mg/kg/day. Finally, atorvastatin decreased the clonal expansion and production of interleukin-2, but not IFN-gamma, by humanCD4+ T cells in response to allogeneic endothelial cells in coculture. CONCLUSIONS: Our results suggest that a benefit of statin administration in transplantation may include amelioration of GA primarily by inhibiting alloreactive T-cell accumulation and consequent IFN-gamma production and secondarily through suppression of the arterial response to IFN-gamma.
Authors: G Tellides; D A Tereb; N C Kirkiles-Smith; R W Kim; J H Wilson; J S Schechner; M I Lorber; J S Pober Journal: Nature Date: 2000-01-13 Impact factor: 49.962
Authors: Robert L Lins; Katelijne E Matthys; Gert A Verpooten; Patrick C Peeters; Max Dratwa; Jean-Claude Stolear; Norbert H Lameire Journal: Nephrol Dial Transplant Date: 2003-05 Impact factor: 5.992
Authors: Hooman Ranjbaran; Seth I Sokol; Amy Gallo; Raymond E Eid; Alexander O Iakimov; Alessio D'Alessio; John R Kapoor; Shamsuddin Akhtar; Christopher J Howes; Mihaela Aslan; Steven Pfau; Jordan S Pober; George Tellides Journal: J Immunol Date: 2007-01-01 Impact factor: 5.422
Authors: Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil Journal: Nature Date: 2002-11-07 Impact factor: 49.962
Authors: Howard J Eisen; E Murat Tuzcu; Richard Dorent; Jon Kobashigawa; Donna Mancini; Hannah A Valantine-von Kaeppler; Randall C Starling; Keld Sørensen; Manfred Hummel; Joan M Lind; Kamal H Abeywickrama; Peter Bernhardt Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Jordan S Pober; Alfred L M Bothwell; Marc I Lorber; Jennifer M McNiff; Jeffrey S Schechner; George Tellides Journal: Springer Semin Immunopathol Date: 2003-09
Authors: Zuzana Tobiasova; Lufeng Zhang; Tai Yi; Linfeng Qin; Thomas D Manes; Sanjay Kulkarni; Marc I Lorber; Frederick C Rodriguez; Je-Min Choi; George Tellides; Jordan S Pober; Ivana Kawikova; Alfred L M Bothwell Journal: Circulation Date: 2011-06-20 Impact factor: 29.690
Authors: Jessica R Golbus; Sarah Adie; Matheos Yosef; Venkatesh L Murthy; Keith D Aaronson; Matthew C Konerman Journal: ESC Heart Fail Date: 2020-06-24
Authors: Lukas Holmegaard; Tara M Stanne; Ulf Andreasson; Henrik Zetterberg; Kaj Blennow; Christian Blomstrand; Katarina Jood; Christina Jern Journal: Acta Neurol Scand Date: 2020-12-04 Impact factor: 3.209